Quantcast
Last updated on April 19, 2014 at 7:22 EDT

Atonomics Achieves Significant Milestone Related to Performance Data for Troponin I Assay Triggering Scheduled Payments From Beckman Coulter

November 26, 2012

COPENHAGEN, Denmark, November 26, 2012 /PRNewswire/ –

Atonomics A/S announced today that it has achieved an important milestone related to a
defined set of performance criteria for a Troponin I assay on the new Atolyzer(R) system.

(Logo:
http://photos.prnewswire.com/prnh/20121126/578019 )

Since entering an equity investment agreement with Beckman Coulter in May of last year
to advance the Atolyzer(R) within cardiac testing, the company has worked diligently to
deliver relevant Troponin I performance data.

“We are pleased to achieve this milestone,” said Thomas Warthoe, Atonomics’ CEO.
“Troponin I is one of the most difficult assays to transfer to a near-patient system and
still deliver data that are comparable to what the physicians get from the central
laboratory; we believe the Atolyzer(R) has the potential to allow physicians in the future
to continue to safely implement data from a near patient system.”

“We expect that this recent and significant achievement will generate appropriate
interest from Industry in order to reach the full potential of the Atolyzer(R) platform,”
said Ashok Dhanrajgir, Chairman of Atonomics board of directors and senior partner with
Inventages Venture Capital

Atonomics’ majority shareholders are Inventages Venture Capital, Sunstone Capital,
NeuroSearch A/S, and Beckman Coulter.

About Atonomics

Atonomics is an emerging technology company based in Copenhagen, Denmark, that designs
and manufactures the innovative Atolyzer(R) system for near-patient testing in hospitals,
clinics, physician offices and patient monitoring. Atonomics is pursuing a strategy to
partner with leading players in the industry to bring a new dimension of quality to the
point-of-care market. The Atolyzer(R) system is a platform for immuno-diagnostic and
molecular diagnostic testing. The Atolyzer(R) is designed for simplicity and ease of use
while preserving performance and safety. The stand-alone device is operated with a single
touch by any health worker and can be positioned in any location throughout the hospital,
clinic or office where large systems cannot operate, representing true near-patient
testing.

        Contacts:

        Atonomics
        Thomas Warthoe, CEO
        Phone: +45-70271330
        Email: tw@atonomics.com
        Web: http://www.atonomics.com


    Photo: 

http://photos.prnewswire.com/prnh/20121126/578019

SOURCE Atonomics A/S


Source: PR Newswire